Skip to main content
. 2020 Jun 4;7(6):992–1001. doi: 10.1002/acn3.51070

Figure 2.

Figure 2

Associations between serum biomarkers and Expanded Disability Status Scale (EDSS) score according to three age groups. (A) Serum neurofilament light chain (NfL) levels and EDSS in MS patients (≤44 years: β = 1.191, P = 0.001; 45–54 years: β = 1.075, P = 0.094; ≥55 years: β = 1.085, P = 0.111), (B) serum glial fibrillary acid protein (GFAP) levels and EDSS in MS patients (≤44 years: β = 1.055, P = 0.149; 45–54 years: β = 1.118, P = 0.028; ≥ 55 years: β = 1.082, P = 0.142), (C) serum NfL levels and EDSS in NMOSD patients (≤44 years: β = 0.866, P = 0.553; 45–54 years: β = 1.031, P = 0.664; ≥55 years: β = 1.290, p = 0.001), (D) serum GFAP levels and EDSS in NMOSD patients (≤44 years: β = 1.222, P = 0.005; 45–54 years: β = 1.149, P = 0.020; ≥55 years: β = 1.025, P = 0.722). MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorders.